Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anticholesteremic Agents | 57 | 2024 | 979 | 12.380 |
Why?
|
Cholesterol, LDL | 63 | 2023 | 2334 | 9.970 |
Why?
|
Myocardial Infarction | 172 | 2024 | 11668 | 8.690 |
Why?
|
Glucosides | 68 | 2024 | 424 | 8.050 |
Why?
|
Benzhydryl Compounds | 75 | 2024 | 819 | 7.220 |
Why?
|
Platelet Aggregation Inhibitors | 86 | 2023 | 3066 | 7.180 |
Why?
|
Acute Coronary Syndrome | 67 | 2023 | 2331 | 5.390 |
Why?
|
Ticlopidine | 44 | 2022 | 899 | 5.230 |
Why?
|
Purinergic P2Y Receptor Antagonists | 23 | 2023 | 361 | 5.170 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 56 | 2023 | 3233 | 5.140 |
Why?
|
Cardiovascular Diseases | 90 | 2024 | 15070 | 4.870 |
Why?
|
Atherosclerosis | 37 | 2023 | 3401 | 4.690 |
Why?
|
Antibodies, Monoclonal | 42 | 2022 | 9259 | 4.300 |
Why?
|
Heart Failure | 103 | 2024 | 10793 | 4.050 |
Why?
|
Adenosine | 17 | 2023 | 819 | 3.980 |
Why?
|
Hypercholesterolemia | 19 | 2022 | 1143 | 3.940 |
Why?
|
Diabetes Mellitus, Type 2 | 62 | 2023 | 11699 | 3.620 |
Why?
|
Thrombolytic Therapy | 50 | 2021 | 2155 | 3.610 |
Why?
|
Serine Proteinase Inhibitors | 7 | 2020 | 179 | 3.610 |
Why?
|
Lipoprotein(a) | 11 | 2024 | 424 | 3.130 |
Why?
|
Proprotein Convertases | 10 | 2015 | 95 | 3.130 |
Why?
|
Coronary Artery Disease | 42 | 2024 | 6416 | 2.530 |
Why?
|
Angina, Unstable | 27 | 2021 | 926 | 2.400 |
Why?
|
Dyslipidemias | 9 | 2020 | 851 | 2.240 |
Why?
|
Stroke | 44 | 2024 | 9898 | 2.180 |
Why?
|
Secondary Prevention | 29 | 2021 | 1516 | 2.180 |
Why?
|
Troponin I | 20 | 2021 | 616 | 2.040 |
Why?
|
Double-Blind Method | 84 | 2022 | 11985 | 2.030 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 7 | 2013 | 257 | 1.930 |
Why?
|
Randomized Controlled Trials as Topic | 59 | 2023 | 9812 | 1.870 |
Why?
|
Hemorrhage | 35 | 2022 | 3441 | 1.830 |
Why?
|
Stroke Volume | 53 | 2024 | 4941 | 1.780 |
Why?
|
Coronary Disease | 32 | 2020 | 6068 | 1.730 |
Why?
|
Aspirin | 21 | 2021 | 3268 | 1.710 |
Why?
|
Treatment Outcome | 140 | 2024 | 62693 | 1.670 |
Why?
|
Ventricular Dysfunction, Left | 16 | 2023 | 2044 | 1.630 |
Why?
|
Heparin | 18 | 2021 | 1637 | 1.610 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 20 | 2018 | 641 | 1.610 |
Why?
|
Drug Therapy, Combination | 48 | 2021 | 6478 | 1.590 |
Why?
|
Peripheral Arterial Disease | 8 | 2023 | 1169 | 1.580 |
Why?
|
Humans | 481 | 2024 | 739398 | 1.570 |
Why?
|
Risk Assessment | 69 | 2023 | 23294 | 1.520 |
Why?
|
Pravastatin | 18 | 2016 | 395 | 1.520 |
Why?
|
Hypolipidemic Agents | 7 | 2021 | 606 | 1.440 |
Why?
|
Myocardial Ischemia | 21 | 2021 | 2146 | 1.440 |
Why?
|
Diabetic Nephropathies | 4 | 2022 | 981 | 1.430 |
Why?
|
Diabetic Cardiomyopathies | 3 | 2019 | 96 | 1.400 |
Why?
|
Fibrinolytic Agents | 25 | 2014 | 2149 | 1.380 |
Why?
|
Cholesterol Ester Transfer Proteins | 2 | 2022 | 113 | 1.380 |
Why?
|
Platelet Aggregation | 11 | 2023 | 801 | 1.360 |
Why?
|
Middle Aged | 236 | 2023 | 212863 | 1.340 |
Why?
|
Aged | 212 | 2024 | 162698 | 1.330 |
Why?
|
Angioplasty, Balloon, Coronary | 20 | 2010 | 1874 | 1.320 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 3 | 2022 | 290 | 1.280 |
Why?
|
Natriuretic Peptide, Brain | 30 | 2023 | 1557 | 1.250 |
Why?
|
Drug-Eluting Stents | 5 | 2021 | 753 | 1.210 |
Why?
|
Pharmacogenetics | 8 | 2022 | 679 | 1.210 |
Why?
|
Hydroxymethylglutaryl CoA Reductases | 2 | 2017 | 59 | 1.190 |
Why?
|
Apolipoproteins B | 7 | 2024 | 373 | 1.190 |
Why?
|
Electrocardiography | 36 | 2021 | 6426 | 1.180 |
Why?
|
Male | 275 | 2023 | 349022 | 1.160 |
Why?
|
Risk Factors | 102 | 2024 | 71974 | 1.160 |
Why?
|
Cardiovascular System | 6 | 2022 | 830 | 1.160 |
Why?
|
Cyclic N-Oxides | 6 | 2021 | 78 | 1.150 |
Why?
|
Hypoglycemic Agents | 12 | 2022 | 2861 | 1.090 |
Why?
|
Coronary Thrombosis | 8 | 2019 | 494 | 1.090 |
Why?
|
Female | 270 | 2023 | 378853 | 1.090 |
Why?
|
Phosphatidylcholine-Sterol O-Acyltransferase | 2 | 2022 | 31 | 1.080 |
Why?
|
Sterol O-Acyltransferase | 2 | 2022 | 27 | 1.070 |
Why?
|
Heptanoic Acids | 12 | 2015 | 343 | 1.010 |
Why?
|
Lipoproteins, LDL | 4 | 2019 | 626 | 1.000 |
Why?
|
Tyrosine | 12 | 2008 | 1460 | 0.970 |
Why?
|
Benzazepines | 4 | 2019 | 326 | 0.960 |
Why?
|
Pyridines | 12 | 2021 | 2810 | 0.960 |
Why?
|
Cholesterol | 9 | 2022 | 2900 | 0.950 |
Why?
|
C-Reactive Protein | 19 | 2019 | 3752 | 0.940 |
Why?
|
Risk Reduction Behavior | 4 | 2020 | 1123 | 0.940 |
Why?
|
Thiophenes | 8 | 2013 | 589 | 0.940 |
Why?
|
Anticoagulants | 16 | 2022 | 4582 | 0.920 |
Why?
|
Blood Platelets | 10 | 2023 | 2506 | 0.880 |
Why?
|
Serine Endopeptidases | 10 | 2015 | 1070 | 0.870 |
Why?
|
Fibroblast Growth Factors | 3 | 2019 | 879 | 0.860 |
Why?
|
Troponin | 7 | 2021 | 516 | 0.850 |
Why?
|
Piperazines | 14 | 2014 | 2480 | 0.850 |
Why?
|
Coronary Artery Bypass | 11 | 2023 | 2272 | 0.840 |
Why?
|
Dose-Response Relationship, Drug | 29 | 2021 | 10945 | 0.840 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2022 | 45 | 0.840 |
Why?
|
Glomerular Filtration Rate | 10 | 2023 | 2184 | 0.830 |
Why?
|
Myocardial Revascularization | 12 | 2021 | 841 | 0.820 |
Why?
|
Genetic Variation | 8 | 2022 | 6539 | 0.810 |
Why?
|
Serotonin 5-HT2 Receptor Agonists | 2 | 2019 | 38 | 0.800 |
Why?
|
Peptide Fragments | 16 | 2023 | 5076 | 0.800 |
Why?
|
Coronary Angiography | 32 | 2022 | 4560 | 0.790 |
Why?
|
Time Factors | 50 | 2021 | 40050 | 0.780 |
Why?
|
Renal Insufficiency, Chronic | 8 | 2023 | 2216 | 0.770 |
Why?
|
Cardiology | 5 | 2021 | 1654 | 0.770 |
Why?
|
Ventricular Function, Left | 23 | 2024 | 3620 | 0.770 |
Why?
|
Venous Thromboembolism | 4 | 2021 | 1673 | 0.760 |
Why?
|
Subtilisin | 1 | 2020 | 12 | 0.760 |
Why?
|
Pyrroles | 12 | 2015 | 1142 | 0.740 |
Why?
|
Thrombosis | 12 | 2022 | 2961 | 0.740 |
Why?
|
Kidney Diseases | 4 | 2020 | 2140 | 0.730 |
Why?
|
Mendelian Randomization Analysis | 5 | 2019 | 950 | 0.730 |
Why?
|
Diabetes Mellitus | 11 | 2022 | 5702 | 0.730 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2021 | 235 | 0.710 |
Why?
|
Cholesterol, VLDL | 2 | 2018 | 65 | 0.710 |
Why?
|
Troponin T | 9 | 2019 | 748 | 0.700 |
Why?
|
Polymorphism, Genetic | 10 | 2010 | 4332 | 0.700 |
Why?
|
Lipase | 1 | 2021 | 315 | 0.700 |
Why?
|
Methylamines | 1 | 2020 | 117 | 0.700 |
Why?
|
Atrial Fibrillation | 10 | 2023 | 5003 | 0.690 |
Why?
|
Hospitalization | 34 | 2023 | 10208 | 0.690 |
Why?
|
Cholesterol, HDL | 10 | 2022 | 1807 | 0.680 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 9 | 2022 | 1510 | 0.680 |
Why?
|
Ultracentrifugation | 2 | 2018 | 182 | 0.670 |
Why?
|
Enoxaparin | 6 | 2009 | 377 | 0.670 |
Why?
|
Platelet Activation | 4 | 2017 | 672 | 0.650 |
Why?
|
Primary Prevention | 6 | 2023 | 1165 | 0.640 |
Why?
|
Phospholipases A2, Secretory | 3 | 2013 | 31 | 0.640 |
Why?
|
Anti-Obesity Agents | 2 | 2018 | 214 | 0.630 |
Why?
|
Recurrence | 27 | 2021 | 8307 | 0.630 |
Why?
|
Aryldialkylphosphatase | 2 | 2016 | 63 | 0.620 |
Why?
|
Indoles | 9 | 2019 | 1832 | 0.620 |
Why?
|
Antithrombins | 3 | 2014 | 304 | 0.610 |
Why?
|
Glucuronidase | 1 | 2019 | 207 | 0.600 |
Why?
|
Atrial Natriuretic Factor | 7 | 2016 | 393 | 0.590 |
Why?
|
Blood Proteins | 3 | 2016 | 1122 | 0.590 |
Why?
|
Follow-Up Studies | 43 | 2021 | 38942 | 0.570 |
Why?
|
Lipid Metabolism Disorders | 1 | 2016 | 19 | 0.570 |
Why?
|
Prognosis | 48 | 2023 | 28901 | 0.560 |
Why?
|
Risk | 20 | 2019 | 9684 | 0.550 |
Why?
|
Proportional Hazards Models | 27 | 2022 | 12328 | 0.550 |
Why?
|
Hyperlipidemias | 2 | 2018 | 785 | 0.540 |
Why?
|
Drug Administration Schedule | 14 | 2019 | 4935 | 0.520 |
Why?
|
Extremities | 1 | 2020 | 849 | 0.510 |
Why?
|
Statistics as Topic | 4 | 2018 | 2373 | 0.500 |
Why?
|
Decision Support Techniques | 4 | 2019 | 1957 | 0.500 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2017 | 705 | 0.490 |
Why?
|
Matrix Metalloproteinases | 2 | 2008 | 391 | 0.490 |
Why?
|
Venous Thrombosis | 2 | 2022 | 1232 | 0.490 |
Why?
|
Renin-Angiotensin System | 1 | 2019 | 763 | 0.480 |
Why?
|
Prodrugs | 2 | 2022 | 271 | 0.480 |
Why?
|
Receptors, LDL | 4 | 2019 | 472 | 0.460 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2021 | 1338 | 0.460 |
Why?
|
Predictive Value of Tests | 28 | 2019 | 15036 | 0.450 |
Why?
|
Lecithins | 2 | 2022 | 16 | 0.440 |
Why?
|
American Heart Association | 5 | 2020 | 1050 | 0.430 |
Why?
|
Acetanilides | 6 | 2014 | 166 | 0.430 |
Why?
|
Diabetic Angiopathies | 3 | 2018 | 821 | 0.420 |
Why?
|
Acute Disease | 25 | 2014 | 7128 | 0.420 |
Why?
|
Growth Differentiation Factor 15 | 3 | 2023 | 177 | 0.420 |
Why?
|
Sleep Apnea Syndromes | 1 | 2020 | 932 | 0.410 |
Why?
|
Cardiovascular Agents | 7 | 2022 | 845 | 0.410 |
Why?
|
Overweight | 4 | 2022 | 2355 | 0.400 |
Why?
|
Subtilisins | 2 | 2022 | 83 | 0.400 |
Why?
|
Peptides | 8 | 2019 | 4395 | 0.400 |
Why?
|
Placebos | 5 | 2021 | 1678 | 0.400 |
Why?
|
Fibrinolysis | 3 | 2011 | 322 | 0.400 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2016 | 371 | 0.390 |
Why?
|
Genotype | 19 | 2022 | 12951 | 0.380 |
Why?
|
Intestines | 1 | 2020 | 1919 | 0.380 |
Why?
|
Clinical Trials as Topic | 12 | 2022 | 7897 | 0.380 |
Why?
|
Epigenomics | 1 | 2016 | 877 | 0.380 |
Why?
|
Proteomics | 5 | 2023 | 3584 | 0.380 |
Why?
|
Blood Coagulation | 3 | 2018 | 1122 | 0.370 |
Why?
|
Calgranulin A | 3 | 2021 | 79 | 0.370 |
Why?
|
Enzyme Inhibitors | 6 | 2015 | 3802 | 0.370 |
Why?
|
Calgranulin B | 3 | 2021 | 84 | 0.370 |
Why?
|
Sodium | 7 | 2022 | 1625 | 0.350 |
Why?
|
Glycopeptides | 4 | 2016 | 223 | 0.350 |
Why?
|
Vascular Diseases | 1 | 2018 | 1152 | 0.350 |
Why?
|
Triglycerides | 5 | 2022 | 2447 | 0.340 |
Why?
|
Angina Pectoris | 8 | 2014 | 976 | 0.340 |
Why?
|
Bacteria | 1 | 2020 | 2106 | 0.340 |
Why?
|
Inflammation | 9 | 2018 | 10534 | 0.330 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2019 | 812 | 0.330 |
Why?
|
Biomedical Research | 5 | 2020 | 3301 | 0.330 |
Why?
|
Lipoprotein Lipase | 2 | 2019 | 126 | 0.320 |
Why?
|
Kidney | 8 | 2023 | 7144 | 0.320 |
Why?
|
Survival Rate | 20 | 2021 | 12761 | 0.320 |
Why?
|
Platelet Function Tests | 4 | 2021 | 270 | 0.320 |
Why?
|
Appetite Depressants | 2 | 2019 | 110 | 0.320 |
Why?
|
Anti-Inflammatory Agents | 1 | 2018 | 1777 | 0.320 |
Why?
|
Interleukins | 2 | 2009 | 788 | 0.320 |
Why?
|
Sodium-Glucose Transporter 2 | 3 | 2023 | 86 | 0.320 |
Why?
|
Blood Glucose | 3 | 2020 | 6237 | 0.320 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2007 | 127 | 0.310 |
Why?
|
Aged, 80 and over | 31 | 2021 | 57650 | 0.310 |
Why?
|
Survival Analysis | 22 | 2019 | 10247 | 0.310 |
Why?
|
Lipoproteins, HDL | 2 | 2022 | 643 | 0.310 |
Why?
|
Myocardial Reperfusion | 5 | 2014 | 351 | 0.310 |
Why?
|
Coronary Aneurysm | 1 | 2010 | 237 | 0.310 |
Why?
|
Puerperal Disorders | 1 | 2010 | 279 | 0.310 |
Why?
|
Aortic Valve Stenosis | 1 | 2020 | 1930 | 0.310 |
Why?
|
Tandem Mass Spectrometry | 3 | 2016 | 1156 | 0.310 |
Why?
|
Thiazoles | 1 | 2015 | 1488 | 0.310 |
Why?
|
Mutation, Missense | 2 | 2017 | 2552 | 0.300 |
Why?
|
Death, Sudden, Cardiac | 6 | 2021 | 1542 | 0.300 |
Why?
|
Disease Progression | 10 | 2023 | 13237 | 0.300 |
Why?
|
Niacin | 2 | 2019 | 116 | 0.300 |
Why?
|
Creatinine | 4 | 2021 | 1903 | 0.300 |
Why?
|
Brain Ischemia | 5 | 2022 | 3246 | 0.300 |
Why?
|
Simvastatin | 3 | 2021 | 360 | 0.290 |
Why?
|
Stents | 10 | 2021 | 3257 | 0.290 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2009 | 419 | 0.290 |
Why?
|
Obesity | 7 | 2022 | 12643 | 0.290 |
Why?
|
Incidence | 19 | 2023 | 20913 | 0.290 |
Why?
|
Lipoproteins | 3 | 2022 | 880 | 0.290 |
Why?
|
Diabetes Mellitus, Experimental | 2 | 2023 | 1125 | 0.290 |
Why?
|
Albuminuria | 3 | 2021 | 692 | 0.280 |
Why?
|
Warfarin | 1 | 2015 | 1484 | 0.280 |
Why?
|
Adult | 52 | 2023 | 213394 | 0.280 |
Why?
|
Receptors, Purinergic P2Y12 | 3 | 2019 | 132 | 0.280 |
Why?
|
Cause of Death | 10 | 2021 | 3564 | 0.280 |
Why?
|
Patient Education as Topic | 2 | 2013 | 2275 | 0.280 |
Why?
|
Injections, Subcutaneous | 2 | 2019 | 664 | 0.280 |
Why?
|
Kaplan-Meier Estimate | 15 | 2020 | 6516 | 0.270 |
Why?
|
Fibrin | 1 | 2008 | 506 | 0.270 |
Why?
|
Research Design | 7 | 2018 | 5959 | 0.270 |
Why?
|
Smoking | 7 | 2019 | 8960 | 0.260 |
Why?
|
Metoprolol | 1 | 2005 | 92 | 0.260 |
Why?
|
Protein Precursors | 5 | 2016 | 1154 | 0.260 |
Why?
|
Odds Ratio | 15 | 2019 | 9846 | 0.260 |
Why?
|
Genetic Predisposition to Disease | 8 | 2022 | 17384 | 0.260 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 3 | 2021 | 691 | 0.250 |
Why?
|
Acute-Phase Proteins | 1 | 2006 | 261 | 0.250 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2010 | 482 | 0.250 |
Why?
|
Apolipoproteins E | 2 | 2012 | 1437 | 0.250 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2005 | 341 | 0.250 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2006 | 300 | 0.250 |
Why?
|
Metabolism | 1 | 2005 | 192 | 0.240 |
Why?
|
Diuretics | 4 | 2022 | 590 | 0.240 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 2 | 2016 | 55 | 0.240 |
Why?
|
Biotransformation | 3 | 2009 | 165 | 0.240 |
Why?
|
Sleep | 1 | 2020 | 4596 | 0.240 |
Why?
|
Adrenomedullin | 2 | 2016 | 87 | 0.240 |
Why?
|
Cyclopropanes | 2 | 2016 | 421 | 0.240 |
Why?
|
Drug Monitoring | 3 | 2021 | 961 | 0.230 |
Why?
|
Severity of Illness Index | 13 | 2020 | 15511 | 0.230 |
Why?
|
Natriuretic Peptides | 1 | 2004 | 150 | 0.230 |
Why?
|
Multicenter Studies as Topic | 6 | 2018 | 1583 | 0.230 |
Why?
|
Neovascularization, Physiologic | 3 | 2023 | 1352 | 0.230 |
Why?
|
Placebo Effect | 4 | 2019 | 503 | 0.230 |
Why?
|
Eosinophilia | 1 | 2007 | 531 | 0.230 |
Why?
|
Europe | 6 | 2022 | 3331 | 0.230 |
Why?
|
Syndrome | 13 | 2008 | 3241 | 0.230 |
Why?
|
Leukocyte Count | 2 | 2008 | 1581 | 0.220 |
Why?
|
Practice Guidelines as Topic | 7 | 2017 | 7274 | 0.220 |
Why?
|
Hemoglobins | 2 | 2009 | 1529 | 0.220 |
Why?
|
Receptors, Cell Surface | 3 | 2011 | 2864 | 0.220 |
Why?
|
Serum Albumin | 2 | 2005 | 669 | 0.220 |
Why?
|
Glucose | 7 | 2022 | 4377 | 0.220 |
Why?
|
Epigenesis, Genetic | 1 | 2016 | 3614 | 0.220 |
Why?
|
MicroRNAs | 3 | 2023 | 3712 | 0.220 |
Why?
|
Myocardium | 6 | 2009 | 4788 | 0.220 |
Why?
|
Biological Assay | 4 | 2015 | 653 | 0.210 |
Why?
|
Heart Failure, Systolic | 1 | 2023 | 123 | 0.210 |
Why?
|
Coronary Circulation | 9 | 2014 | 1578 | 0.210 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2022 | 91 | 0.210 |
Why?
|
Infusions, Subcutaneous | 1 | 2021 | 42 | 0.210 |
Why?
|
Azetidines | 2 | 2014 | 142 | 0.210 |
Why?
|
Lactones | 2 | 2016 | 329 | 0.210 |
Why?
|
Patient Care Planning | 2 | 2017 | 918 | 0.210 |
Why?
|
Sex Characteristics | 4 | 2022 | 2583 | 0.200 |
Why?
|
No-Reflow Phenomenon | 1 | 2021 | 14 | 0.200 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2013 | 1238 | 0.200 |
Why?
|
Disease Management | 6 | 2021 | 2448 | 0.200 |
Why?
|
Hypokalemia | 1 | 2022 | 154 | 0.190 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 68 | 0.190 |
Why?
|
Heterozygote | 5 | 2011 | 2798 | 0.190 |
Why?
|
Peroxidase | 3 | 2016 | 608 | 0.190 |
Why?
|
Endophenotypes | 1 | 2022 | 250 | 0.190 |
Why?
|
Prospective Studies | 26 | 2022 | 53037 | 0.190 |
Why?
|
Chest Pain | 4 | 2014 | 1112 | 0.180 |
Why?
|
Myocarditis | 1 | 2007 | 760 | 0.180 |
Why?
|
Weight Loss | 4 | 2019 | 2589 | 0.180 |
Why?
|
Hyperkalemia | 1 | 2022 | 219 | 0.180 |
Why?
|
Glomerulonephritis | 1 | 2002 | 370 | 0.180 |
Why?
|
Multivariate Analysis | 13 | 2013 | 12237 | 0.180 |
Why?
|
Lipolysis | 2 | 2018 | 211 | 0.180 |
Why?
|
Diabetes Complications | 3 | 2020 | 1356 | 0.180 |
Why?
|
Angiotensin Receptor Antagonists | 3 | 2022 | 919 | 0.170 |
Why?
|
Reperfusion | 1 | 2000 | 283 | 0.170 |
Why?
|
Purinergic P2 Receptor Antagonists | 2 | 2009 | 71 | 0.170 |
Why?
|
Case-Control Studies | 8 | 2020 | 21694 | 0.170 |
Why?
|
Up-Regulation | 2 | 2020 | 4205 | 0.170 |
Why?
|
Cognition | 5 | 2022 | 6686 | 0.170 |
Why?
|
Hyponatremia | 1 | 2022 | 296 | 0.170 |
Why?
|
Central Nervous System Stimulants | 1 | 2007 | 1146 | 0.170 |
Why?
|
Drug Hypersensitivity | 1 | 2007 | 889 | 0.170 |
Why?
|
Cardiac Pacing, Artificial | 2 | 2014 | 847 | 0.170 |
Why?
|
Whole Blood Coagulation Time | 1 | 2018 | 29 | 0.160 |
Why?
|
Biphenyl Compounds | 2 | 2020 | 909 | 0.160 |
Why?
|
Appetite Regulation | 1 | 2019 | 88 | 0.160 |
Why?
|
P-Selectin | 1 | 2021 | 600 | 0.160 |
Why?
|
Ischemia | 4 | 2023 | 1908 | 0.160 |
Why?
|
Genome-Wide Association Study | 8 | 2022 | 12178 | 0.160 |
Why?
|
Immunoassay | 4 | 2010 | 750 | 0.160 |
Why?
|
Coronary Restenosis | 1 | 2021 | 423 | 0.160 |
Why?
|
Adamantane | 1 | 2019 | 173 | 0.160 |
Why?
|
Embolism, Cholesterol | 1 | 1997 | 34 | 0.160 |
Why?
|
Diuresis | 1 | 2018 | 116 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2022 | 451 | 0.160 |
Why?
|
Postoperative Complications | 1 | 2020 | 15194 | 0.160 |
Why?
|
United States | 21 | 2024 | 69573 | 0.160 |
Why?
|
Symporters | 1 | 2020 | 364 | 0.150 |
Why?
|
Drug Therapy | 1 | 2021 | 497 | 0.150 |
Why?
|
Intracranial Hemorrhages | 4 | 2018 | 846 | 0.150 |
Why?
|
Mevalonic Acid | 1 | 2017 | 41 | 0.150 |
Why?
|
Genomic Structural Variation | 1 | 2017 | 65 | 0.150 |
Why?
|
Drug Labeling | 1 | 2019 | 230 | 0.150 |
Why?
|
Comorbidity | 9 | 2023 | 10362 | 0.150 |
Why?
|
Sensitivity and Specificity | 13 | 2016 | 14740 | 0.150 |
Why?
|
Drug Design | 2 | 2015 | 1088 | 0.150 |
Why?
|
Arteritis | 1 | 2019 | 159 | 0.150 |
Why?
|
Renal Insufficiency | 3 | 2019 | 803 | 0.150 |
Why?
|
Dipeptides | 1 | 2019 | 409 | 0.150 |
Why?
|
Norway | 2 | 2015 | 445 | 0.150 |
Why?
|
Homozygote | 3 | 2011 | 1788 | 0.150 |
Why?
|
Clinical Chemistry Tests | 2 | 2015 | 61 | 0.150 |
Why?
|
Guideline Adherence | 2 | 2020 | 2261 | 0.150 |
Why?
|
Patient Selection | 4 | 2019 | 4211 | 0.140 |
Why?
|
Creatine Kinase, MB Form | 4 | 2014 | 214 | 0.140 |
Why?
|
RNA, Small Interfering | 2 | 2023 | 3498 | 0.140 |
Why?
|
Pyrrolidines | 5 | 2007 | 342 | 0.140 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2019 | 386 | 0.140 |
Why?
|
Gout | 1 | 2023 | 547 | 0.140 |
Why?
|
Endothelin-1 | 2 | 2023 | 313 | 0.140 |
Why?
|
Patients | 1 | 2023 | 890 | 0.140 |
Why?
|
Probability | 6 | 2010 | 2500 | 0.140 |
Why?
|
Least-Squares Analysis | 1 | 2017 | 382 | 0.140 |
Why?
|
Alanine | 5 | 2007 | 578 | 0.140 |
Why?
|
Metformin | 2 | 2020 | 827 | 0.140 |
Why?
|
Acute Kidney Injury | 2 | 2022 | 1941 | 0.140 |
Why?
|
Collagen Type I | 1 | 2019 | 577 | 0.140 |
Why?
|
Pulmonary Embolism | 2 | 2020 | 2365 | 0.140 |
Why?
|
Vascular Patency | 4 | 2010 | 888 | 0.140 |
Why?
|
Hypoglycemia | 3 | 2019 | 855 | 0.140 |
Why?
|
Withholding Treatment | 1 | 2020 | 596 | 0.140 |
Why?
|
Ventricular Fibrillation | 2 | 2009 | 539 | 0.130 |
Why?
|
Anemia | 2 | 2021 | 1498 | 0.130 |
Why?
|
Morphine | 1 | 2020 | 655 | 0.130 |
Why?
|
Neutrophils | 1 | 2008 | 3698 | 0.130 |
Why?
|
Tachycardia, Ventricular | 3 | 2009 | 1271 | 0.130 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 1998 | 592 | 0.130 |
Why?
|
Limb Salvage | 1 | 2017 | 433 | 0.130 |
Why?
|
Mass Spectrometry | 3 | 2014 | 2200 | 0.130 |
Why?
|
Tissue Plasminogen Activator | 2 | 2004 | 1263 | 0.130 |
Why?
|
Combined Modality Therapy | 6 | 2019 | 8605 | 0.130 |
Why?
|
Aptamers, Nucleotide | 1 | 2016 | 166 | 0.130 |
Why?
|
Cost-Benefit Analysis | 5 | 2024 | 5462 | 0.130 |
Why?
|
Research Personnel | 1 | 2020 | 571 | 0.130 |
Why?
|
Partial Thromboplastin Time | 2 | 2009 | 203 | 0.120 |
Why?
|
Oxidative Stress | 1 | 2006 | 3087 | 0.120 |
Why?
|
Exercise Test | 3 | 2008 | 2069 | 0.120 |
Why?
|
Resistin | 1 | 2015 | 170 | 0.120 |
Why?
|
Haplotypes | 3 | 2009 | 2782 | 0.120 |
Why?
|
Galectin 3 | 1 | 2016 | 226 | 0.120 |
Why?
|
Logistic Models | 8 | 2013 | 13402 | 0.120 |
Why?
|
Pulmonary Edema | 2 | 2007 | 415 | 0.120 |
Why?
|
Vascular Grafting | 1 | 2016 | 142 | 0.120 |
Why?
|
Drug Discovery | 1 | 2022 | 1056 | 0.120 |
Why?
|
Prehypertension | 1 | 2014 | 61 | 0.120 |
Why?
|
DNA | 3 | 2013 | 7275 | 0.120 |
Why?
|
Markov Chains | 1 | 2017 | 970 | 0.120 |
Why?
|
Aortic Diseases | 1 | 2020 | 734 | 0.120 |
Why?
|
Hirudins | 1 | 2014 | 182 | 0.120 |
Why?
|
Treatment Failure | 5 | 2019 | 2614 | 0.120 |
Why?
|
Necrosis | 2 | 2023 | 1643 | 0.110 |
Why?
|
Galectins | 1 | 2016 | 266 | 0.110 |
Why?
|
Endothelium, Vascular | 1 | 2006 | 4454 | 0.110 |
Why?
|
Down-Regulation | 2 | 2018 | 2999 | 0.110 |
Why?
|
Endoscopy, Gastrointestinal | 2 | 2009 | 857 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 7 | 2019 | 15500 | 0.110 |
Why?
|
International Normalized Ratio | 1 | 2015 | 365 | 0.110 |
Why?
|
Cohort Studies | 11 | 2023 | 40389 | 0.110 |
Why?
|
Epidemiologic Methods | 2 | 2008 | 1364 | 0.110 |
Why?
|
CD40 Ligand | 2 | 2021 | 527 | 0.110 |
Why?
|
Drug Approval | 1 | 2019 | 742 | 0.110 |
Why?
|
Chemokine CCL2 | 2 | 2007 | 618 | 0.110 |
Why?
|
Cerebral Infarction | 1 | 2018 | 1004 | 0.110 |
Why?
|
Quality of Life | 5 | 2023 | 12640 | 0.110 |
Why?
|
Gene Expression Regulation | 5 | 2013 | 12049 | 0.110 |
Why?
|
Plasminogen Activators | 2 | 2005 | 209 | 0.110 |
Why?
|
Australia | 1 | 2015 | 1162 | 0.110 |
Why?
|
Death | 2 | 2020 | 670 | 0.110 |
Why?
|
Alleles | 4 | 2018 | 6942 | 0.110 |
Why?
|
Bone Density Conservation Agents | 1 | 2019 | 771 | 0.110 |
Why?
|
Bile Acids and Salts | 1 | 2014 | 354 | 0.100 |
Why?
|
Random Allocation | 1 | 2016 | 2417 | 0.100 |
Why?
|
Benzodiazepines | 1 | 2018 | 1099 | 0.100 |
Why?
|
Heart | 3 | 2019 | 4466 | 0.100 |
Why?
|
Reference Values | 5 | 2019 | 4983 | 0.100 |
Why?
|
Administration, Oral | 2 | 2015 | 3909 | 0.100 |
Why?
|
Receptor, PAR-1 | 1 | 2012 | 114 | 0.100 |
Why?
|
Genetic Loci | 2 | 2012 | 2567 | 0.100 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2018 | 618 | 0.100 |
Why?
|
Editorial Policies | 1 | 2016 | 446 | 0.100 |
Why?
|
Clinical Enzyme Tests | 1 | 2011 | 114 | 0.100 |
Why?
|
Heart Arrest | 1 | 2021 | 1458 | 0.100 |
Why?
|
Osteoprotegerin | 1 | 2012 | 174 | 0.100 |
Why?
|
Aneurysm, Infected | 1 | 2012 | 85 | 0.100 |
Why?
|
Pregnancy Proteins | 1 | 2012 | 229 | 0.100 |
Why?
|
Registries | 7 | 2020 | 8039 | 0.100 |
Why?
|
Amino Acid Substitution | 1 | 2016 | 1793 | 0.100 |
Why?
|
Injections, Intravenous | 2 | 2013 | 1421 | 0.100 |
Why?
|
Peptide Mapping | 1 | 2011 | 263 | 0.100 |
Why?
|
Animals | 18 | 2023 | 168368 | 0.100 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1689 | 0.100 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2012 | 314 | 0.100 |
Why?
|
China | 3 | 2020 | 2225 | 0.100 |
Why?
|
Hospitals | 2 | 2020 | 3916 | 0.100 |
Why?
|
Cytokines | 1 | 2006 | 7298 | 0.100 |
Why?
|
Coronary Vessels | 3 | 2012 | 3097 | 0.100 |
Why?
|
Hypertension | 3 | 2022 | 8431 | 0.100 |
Why?
|
Patient Discharge | 2 | 2010 | 3286 | 0.100 |
Why?
|
Cardiomyopathies | 1 | 2022 | 1911 | 0.090 |
Why?
|
Reproducibility of Results | 6 | 2021 | 19811 | 0.090 |
Why?
|
Phospholipases A2 | 2 | 2007 | 203 | 0.090 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 686 | 0.090 |
Why?
|
Organizational Objectives | 1 | 2012 | 439 | 0.090 |
Why?
|
Perioperative Care | 2 | 2016 | 995 | 0.090 |
Why?
|
Indicator Dilution Techniques | 1 | 2009 | 41 | 0.090 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 2010 | 293 | 0.090 |
Why?
|
Drugs, Investigational | 1 | 2012 | 215 | 0.090 |
Why?
|
Proteome | 2 | 2011 | 1772 | 0.090 |
Why?
|
Cholecalciferol | 1 | 2014 | 534 | 0.090 |
Why?
|
Algorithms | 6 | 2020 | 13872 | 0.090 |
Why?
|
Lipids | 2 | 2020 | 3307 | 0.090 |
Why?
|
Blood Chemical Analysis | 1 | 2011 | 441 | 0.090 |
Why?
|
Microsomes, Liver | 1 | 2009 | 176 | 0.090 |
Why?
|
Advisory Committees | 3 | 2020 | 770 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5502 | 0.080 |
Why?
|
Patient Care | 1 | 2014 | 638 | 0.080 |
Why?
|
Chemistry, Clinical | 1 | 2009 | 64 | 0.080 |
Why?
|
Myocardial Contraction | 1 | 2014 | 1585 | 0.080 |
Why?
|
Analysis of Variance | 5 | 2012 | 6370 | 0.080 |
Why?
|
Fatal Outcome | 2 | 2007 | 1850 | 0.080 |
Why?
|
Proton Pump Inhibitors | 2 | 2013 | 519 | 0.080 |
Why?
|
Infusions, Intravenous | 2 | 2013 | 2270 | 0.080 |
Why?
|
Molecular Targeted Therapy | 2 | 2022 | 2727 | 0.080 |
Why?
|
Dyspnea | 1 | 2016 | 1295 | 0.080 |
Why?
|
Emergency Medical Services | 2 | 2012 | 1904 | 0.080 |
Why?
|
Lower Extremity | 1 | 2016 | 1145 | 0.080 |
Why?
|
Chromatography, Affinity | 1 | 2009 | 550 | 0.080 |
Why?
|
Information Dissemination | 1 | 2016 | 1106 | 0.080 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2009 | 153 | 0.080 |
Why?
|
Oximes | 2 | 2018 | 309 | 0.080 |
Why?
|
Blood | 1 | 2010 | 597 | 0.080 |
Why?
|
Neopterin | 1 | 2007 | 56 | 0.080 |
Why?
|
Endocarditis | 1 | 2012 | 346 | 0.080 |
Why?
|
Isotope Labeling | 1 | 2009 | 415 | 0.080 |
Why?
|
Metabolome | 1 | 2014 | 881 | 0.080 |
Why?
|
Drug Combinations | 3 | 2020 | 1959 | 0.080 |
Why?
|
Memory | 1 | 2017 | 2161 | 0.080 |
Why?
|
Retrospective Studies | 15 | 2023 | 76631 | 0.080 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2016 | 1257 | 0.080 |
Why?
|
Genetic Heterogeneity | 1 | 2010 | 727 | 0.070 |
Why?
|
Leptin | 1 | 2015 | 1589 | 0.070 |
Why?
|
Heart Conduction System | 2 | 2003 | 1049 | 0.070 |
Why?
|
Immunologic Factors | 1 | 2016 | 1571 | 0.070 |
Why?
|
Multifactorial Inheritance | 2 | 2022 | 1174 | 0.070 |
Why?
|
Protein Conformation | 1 | 2015 | 4012 | 0.070 |
Why?
|
Diagnosis, Differential | 4 | 2010 | 12948 | 0.070 |
Why?
|
Reference Standards | 2 | 2008 | 1018 | 0.070 |
Why?
|
Hyperemia | 1 | 2008 | 224 | 0.070 |
Why?
|
Uric Acid | 2 | 2023 | 753 | 0.070 |
Why?
|
Asparagine | 1 | 2006 | 123 | 0.070 |
Why?
|
Safety | 2 | 2009 | 1186 | 0.070 |
Why?
|
Heart Injuries | 1 | 2008 | 210 | 0.070 |
Why?
|
Sentinel Surveillance | 1 | 2008 | 291 | 0.070 |
Why?
|
Premedication | 1 | 2007 | 257 | 0.070 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3029 | 0.070 |
Why?
|
Health Status | 1 | 2019 | 4013 | 0.070 |
Why?
|
Sex Distribution | 3 | 2013 | 2296 | 0.070 |
Why?
|
Prosthesis-Related Infections | 1 | 2012 | 538 | 0.070 |
Why?
|
Evidence-Based Medicine | 3 | 2014 | 3606 | 0.070 |
Why?
|
Carotid Artery Diseases | 1 | 2012 | 879 | 0.070 |
Why?
|
Cell Adhesion Molecules | 2 | 2017 | 1599 | 0.070 |
Why?
|
International Cooperation | 1 | 2012 | 1420 | 0.070 |
Why?
|
Angiogenic Proteins | 1 | 2006 | 104 | 0.070 |
Why?
|
Immunoglobulin Fab Fragments | 3 | 2004 | 482 | 0.070 |
Why?
|
Pericardial Effusion | 1 | 2007 | 241 | 0.070 |
Why?
|
Citric Acid | 1 | 2005 | 126 | 0.070 |
Why?
|
Phospholipases A | 1 | 2006 | 216 | 0.070 |
Why?
|
Cardiac Output, Low | 1 | 2006 | 193 | 0.070 |
Why?
|
Echocardiography | 1 | 2018 | 5098 | 0.070 |
Why?
|
Young Adult | 8 | 2023 | 56255 | 0.060 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 694 | 0.060 |
Why?
|
Linkage Disequilibrium | 2 | 2010 | 1992 | 0.060 |
Why?
|
Data Collection | 1 | 2014 | 3341 | 0.060 |
Why?
|
Adiponectin | 1 | 2011 | 1096 | 0.060 |
Why?
|
Cooperative Behavior | 1 | 2012 | 1503 | 0.060 |
Why?
|
Lipid Metabolism | 2 | 2014 | 1891 | 0.060 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1327 | 0.060 |
Why?
|
Ventricular Function | 1 | 2006 | 416 | 0.060 |
Why?
|
Phenotype | 4 | 2016 | 16301 | 0.060 |
Why?
|
Research Report | 2 | 2019 | 351 | 0.060 |
Why?
|
Plasma | 1 | 2008 | 573 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 1998 | 4143 | 0.060 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2012 | 1539 | 0.060 |
Why?
|
Graft Rejection | 1 | 1998 | 4379 | 0.060 |
Why?
|
Recombinant Proteins | 1 | 2014 | 6610 | 0.060 |
Why?
|
Sex Factors | 6 | 2021 | 10398 | 0.060 |
Why?
|
Area Under Curve | 1 | 2008 | 1655 | 0.060 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 277 | 0.060 |
Why?
|
History, 20th Century | 1 | 2012 | 2742 | 0.060 |
Why?
|
Circadian Rhythm | 2 | 2013 | 2614 | 0.060 |
Why?
|
Body Height | 1 | 2010 | 1577 | 0.060 |
Why?
|
Cardiotonic Agents | 2 | 2008 | 535 | 0.060 |
Why?
|
Aspartic Acid | 1 | 2006 | 575 | 0.060 |
Why?
|
Stress, Physiological | 1 | 2011 | 1405 | 0.060 |
Why?
|
Societies, Medical | 1 | 2016 | 3739 | 0.060 |
Why?
|
Life Tables | 1 | 2004 | 370 | 0.060 |
Why?
|
Adenosine Monophosphate | 1 | 2005 | 277 | 0.060 |
Why?
|
Prediabetic State | 2 | 2019 | 484 | 0.060 |
Why?
|
Platelet Count | 1 | 2006 | 780 | 0.060 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 3650 | 0.060 |
Why?
|
Growth Substances | 1 | 2006 | 784 | 0.060 |
Why?
|
Blood Pressure | 4 | 2022 | 8554 | 0.060 |
Why?
|
Iceland | 1 | 2023 | 182 | 0.060 |
Why?
|
Age Factors | 5 | 2019 | 18349 | 0.060 |
Why?
|
Data Interpretation, Statistical | 2 | 2014 | 2716 | 0.060 |
Why?
|
Exanthema | 1 | 2007 | 491 | 0.060 |
Why?
|
Fees, Pharmaceutical | 1 | 2002 | 64 | 0.050 |
Why?
|
Receptors, Fc | 1 | 2006 | 539 | 0.050 |
Why?
|
Staphylococcal Infections | 1 | 2012 | 1403 | 0.050 |
Why?
|
Muscle, Skeletal | 2 | 2010 | 4920 | 0.050 |
Why?
|
Safety Management | 1 | 2008 | 782 | 0.050 |
Why?
|
Stress, Mechanical | 1 | 2008 | 1682 | 0.050 |
Why?
|
Adolescent | 8 | 2012 | 85405 | 0.050 |
Why?
|
Inhibins | 1 | 2023 | 212 | 0.050 |
Why?
|
Myocytes, Cardiac | 2 | 2008 | 1625 | 0.050 |
Why?
|
Patient Participation | 1 | 2011 | 1441 | 0.050 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2007 | 519 | 0.050 |
Why?
|
Receptors, Erythropoietin | 1 | 2022 | 147 | 0.050 |
Why?
|
Myoglobin | 1 | 2002 | 160 | 0.050 |
Why?
|
Drug Interactions | 3 | 2013 | 1456 | 0.050 |
Why?
|
Antigens, CD | 2 | 2006 | 4024 | 0.050 |
Why?
|
Monocytes | 2 | 2012 | 2583 | 0.050 |
Why?
|
Colchicine | 1 | 2023 | 240 | 0.050 |
Why?
|
Hospital Mortality | 6 | 2020 | 5305 | 0.050 |
Why?
|
DNA Methylation | 1 | 2016 | 4269 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2023 | 13880 | 0.050 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2005 | 1580 | 0.050 |
Why?
|
Age Distribution | 2 | 2013 | 2904 | 0.050 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2022 | 216 | 0.050 |
Why?
|
Hypotension | 1 | 2007 | 881 | 0.050 |
Why?
|
Placenta | 1 | 2010 | 1682 | 0.050 |
Why?
|
Arginine | 2 | 2005 | 945 | 0.050 |
Why?
|
Sulfoxides | 1 | 2000 | 48 | 0.050 |
Why?
|
Alzheimer Disease | 1 | 2022 | 7975 | 0.050 |
Why?
|
Coronary Sinus | 2 | 2014 | 87 | 0.050 |
Why?
|
Ceramides | 1 | 2022 | 199 | 0.050 |
Why?
|
Bleeding Time | 1 | 2000 | 89 | 0.050 |
Why?
|
Benzamidines | 1 | 2000 | 25 | 0.050 |
Why?
|
Receptors, Transferrin | 1 | 2022 | 297 | 0.050 |
Why?
|
Aging | 1 | 2019 | 8613 | 0.050 |
Why?
|
Bilirubin | 1 | 2022 | 415 | 0.050 |
Why?
|
Chronic Disease | 4 | 2023 | 9133 | 0.050 |
Why?
|
Africa | 1 | 2022 | 666 | 0.050 |
Why?
|
Antibodies | 1 | 2009 | 2450 | 0.050 |
Why?
|
Insulin | 3 | 2023 | 6569 | 0.050 |
Why?
|
Radionuclide Imaging | 1 | 2004 | 2028 | 0.050 |
Why?
|
Lactic Acid | 1 | 2005 | 1132 | 0.050 |
Why?
|
Hematocrit | 1 | 2022 | 636 | 0.050 |
Why?
|
Pipecolic Acids | 1 | 2000 | 76 | 0.050 |
Why?
|
Fever | 1 | 2007 | 1607 | 0.050 |
Why?
|
Endothelial Cells | 2 | 2023 | 3435 | 0.050 |
Why?
|
Body Weight | 2 | 2023 | 4660 | 0.040 |
Why?
|
Databases, Factual | 2 | 2021 | 7690 | 0.040 |
Why?
|
Ferritins | 1 | 2022 | 589 | 0.040 |
Why?
|
Death, Sudden | 1 | 2021 | 298 | 0.040 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2022 | 502 | 0.040 |
Why?
|
Drug Evaluation | 1 | 2000 | 637 | 0.040 |
Why?
|
ROC Curve | 3 | 2014 | 3526 | 0.040 |
Why?
|
Age of Onset | 1 | 2006 | 3263 | 0.040 |
Why?
|
Acetates | 1 | 2000 | 313 | 0.040 |
Why?
|
Clinical Protocols | 1 | 2005 | 1453 | 0.040 |
Why?
|
Body Mass Index | 3 | 2023 | 12655 | 0.040 |
Why?
|
Coronary Care Units | 1 | 2000 | 214 | 0.040 |
Why?
|
Energy Metabolism | 1 | 2010 | 2896 | 0.040 |
Why?
|
Prevalence | 4 | 2021 | 15153 | 0.040 |
Why?
|
Virulence | 1 | 2022 | 1321 | 0.040 |
Why?
|
Benzaldehydes | 1 | 2018 | 58 | 0.040 |
Why?
|
Phospholipids | 1 | 2022 | 783 | 0.040 |
Why?
|
Respiratory Insufficiency | 1 | 2007 | 1197 | 0.040 |
Why?
|
Mice | 7 | 2023 | 81002 | 0.040 |
Why?
|
Plectin | 1 | 2017 | 14 | 0.040 |
Why?
|
Peptides, Cyclic | 1 | 2000 | 400 | 0.040 |
Why?
|
Pedigree | 1 | 2006 | 4640 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 3497 | 0.040 |
Why?
|
Apolipoprotein E4 | 1 | 2022 | 669 | 0.040 |
Why?
|
Drug Dosage Calculations | 1 | 2018 | 113 | 0.040 |
Why?
|
Anti-Glomerular Basement Membrane Disease | 1 | 1997 | 42 | 0.040 |
Why?
|
Potassium | 1 | 2022 | 1337 | 0.040 |
Why?
|
Myosin Light Chains | 1 | 2017 | 121 | 0.040 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2018 | 183 | 0.040 |
Why?
|
H-2 Antigens | 1 | 1998 | 365 | 0.040 |
Why?
|
Chi-Square Distribution | 3 | 2010 | 3510 | 0.040 |
Why?
|
Confidence Intervals | 3 | 2010 | 2974 | 0.040 |
Why?
|
Liver | 2 | 2022 | 7449 | 0.040 |
Why?
|
North America | 1 | 2020 | 1249 | 0.040 |
Why?
|
Endpoint Determination | 1 | 2019 | 598 | 0.040 |
Why?
|
Aortic Aneurysm | 1 | 2001 | 643 | 0.040 |
Why?
|
Blood Flow Velocity | 1 | 2000 | 1437 | 0.040 |
Why?
|
Radiography | 1 | 2007 | 6998 | 0.040 |
Why?
|
Diabetic Ketoacidosis | 1 | 2019 | 246 | 0.040 |
Why?
|
Femoral Artery | 1 | 2000 | 841 | 0.030 |
Why?
|
Solubility | 1 | 1998 | 1083 | 0.030 |
Why?
|
Apolipoprotein A-I | 1 | 2017 | 281 | 0.030 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 1998 | 279 | 0.030 |
Why?
|
Florida | 1 | 2017 | 437 | 0.030 |
Why?
|
England | 1 | 2017 | 522 | 0.030 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 1998 | 358 | 0.030 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2002 | 678 | 0.030 |
Why?
|
Diet, Reducing | 1 | 2019 | 460 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2022 | 1778 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2020 | 706 | 0.030 |
Why?
|
Self-Assessment | 1 | 2017 | 390 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2023 | 1997 | 0.030 |
Why?
|
Psychological Tests | 1 | 2017 | 649 | 0.030 |
Why?
|
Hep G2 Cells | 1 | 2016 | 392 | 0.030 |
Why?
|
Sarcomeres | 1 | 2017 | 373 | 0.030 |
Why?
|
DNA, Single-Stranded | 1 | 2016 | 351 | 0.030 |
Why?
|
Osteoporotic Fractures | 1 | 2019 | 400 | 0.030 |
Why?
|
beta 2-Microglobulin | 1 | 1995 | 316 | 0.030 |
Why?
|
Ultrasonography | 1 | 2007 | 5941 | 0.030 |
Why?
|
Population | 1 | 2014 | 142 | 0.030 |
Why?
|
Metabolic Networks and Pathways | 1 | 2019 | 781 | 0.030 |
Why?
|
Tryptophan Hydroxylase | 1 | 2014 | 89 | 0.030 |
Why?
|
Aortic Valve Insufficiency | 1 | 2018 | 576 | 0.030 |
Why?
|
Rabbits | 1 | 2000 | 4882 | 0.030 |
Why?
|
Proteins | 1 | 2009 | 6082 | 0.030 |
Why?
|
Iron | 1 | 2022 | 1776 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 766 | 0.030 |
Why?
|
Exercise | 1 | 2010 | 5591 | 0.030 |
Why?
|
NF-kappa B | 1 | 2022 | 2502 | 0.030 |
Why?
|
Intensive Care Units | 1 | 2007 | 3672 | 0.030 |
Why?
|
Heterocyclic Compounds | 1 | 2014 | 248 | 0.030 |
Why?
|
Sodium Channel Blockers | 1 | 2014 | 176 | 0.030 |
Why?
|
Spinal Fractures | 1 | 2019 | 697 | 0.030 |
Why?
|
Remission Induction | 1 | 2018 | 2378 | 0.030 |
Why?
|
Limit of Detection | 1 | 2013 | 264 | 0.030 |
Why?
|
Outpatients | 1 | 2020 | 1469 | 0.030 |
Why?
|
Genome, Human | 1 | 2006 | 4419 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2016 | 977 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2000 | 1170 | 0.030 |
Why?
|
Gene Frequency | 2 | 2010 | 3585 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2022 | 2039 | 0.030 |
Why?
|
Pregnancy | 2 | 2012 | 29002 | 0.030 |
Why?
|
Heart Rate | 1 | 2023 | 4095 | 0.030 |
Why?
|
Carbohydrates | 1 | 2014 | 387 | 0.030 |
Why?
|
Piperidines | 1 | 2000 | 1597 | 0.030 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 1995 | 562 | 0.030 |
Why?
|
Rupture, Spontaneous | 1 | 2012 | 354 | 0.030 |
Why?
|
Internationality | 1 | 2017 | 1004 | 0.030 |
Why?
|
Cytochrome P-450 CYP1A2 | 1 | 2011 | 68 | 0.030 |
Why?
|
Thyroid Hormones | 1 | 2014 | 387 | 0.030 |
Why?
|
Nerve Tissue Proteins | 1 | 2004 | 4463 | 0.030 |
Why?
|
Long-Term Care | 1 | 2015 | 606 | 0.020 |
Why?
|
Microfilament Proteins | 1 | 2017 | 1150 | 0.020 |
Why?
|
Arrhythmias, Cardiac | 1 | 2021 | 2265 | 0.020 |
Why?
|
Hip Fractures | 1 | 2019 | 953 | 0.020 |
Why?
|
Interleukin-11 | 1 | 2010 | 62 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2005 | 3844 | 0.020 |
Why?
|
Sulfonamides | 1 | 2000 | 1934 | 0.020 |
Why?
|
Medicare | 2 | 2024 | 6497 | 0.020 |
Why?
|
Smad3 Protein | 1 | 2010 | 178 | 0.020 |
Why?
|
Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2010 | 70 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 2913 | 0.020 |
Why?
|
Preventive Health Services | 1 | 2015 | 576 | 0.020 |
Why?
|
Anti-Infective Agents | 2 | 2007 | 973 | 0.020 |
Why?
|
Genetic Testing | 2 | 2013 | 3441 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2019 | 1957 | 0.020 |
Why?
|
Sampling Studies | 1 | 2011 | 624 | 0.020 |
Why?
|
Contrast Media | 1 | 2003 | 5293 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 1998 | 6310 | 0.020 |
Why?
|
Standard of Care | 1 | 2013 | 563 | 0.020 |
Why?
|
Transfection | 1 | 1998 | 5884 | 0.020 |
Why?
|
Critical Illness | 1 | 2022 | 2656 | 0.020 |
Why?
|
Systems Integration | 1 | 2011 | 441 | 0.020 |
Why?
|
Embolism | 1 | 2012 | 408 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2022 | 6963 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 1998 | 3770 | 0.020 |
Why?
|
Mice, Inbred C57BL | 3 | 2012 | 21863 | 0.020 |
Why?
|
Isotopes | 1 | 2008 | 123 | 0.020 |
Why?
|
Histocompatibility Antigens Class I | 1 | 1995 | 1359 | 0.020 |
Why?
|
Child, Preschool | 2 | 2022 | 40802 | 0.020 |
Why?
|
Digitalis Glycosides | 1 | 2008 | 47 | 0.020 |
Why?
|
Diagnosis-Related Groups | 1 | 2010 | 453 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2012 | 18003 | 0.020 |
Why?
|
Amino Acids | 1 | 2014 | 1727 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2017 | 2440 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3863 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2018 | 1525 | 0.020 |
Why?
|
Fractures, Bone | 1 | 2019 | 1939 | 0.020 |
Why?
|
Graft Survival | 1 | 1998 | 3723 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2009 | 13816 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2004 | 7862 | 0.020 |
Why?
|
Propensity Score | 1 | 2013 | 1749 | 0.020 |
Why?
|
Scotland | 1 | 2006 | 155 | 0.020 |
Why?
|
Bone Density | 1 | 2019 | 3471 | 0.020 |
Why?
|
Research | 1 | 2015 | 2001 | 0.020 |
Why?
|
Ventricular Pressure | 1 | 2007 | 199 | 0.020 |
Why?
|
Ambulances | 1 | 2006 | 95 | 0.020 |
Why?
|
Graft Occlusion, Vascular | 1 | 2009 | 551 | 0.020 |
Why?
|
Pacemaker, Artificial | 1 | 2012 | 813 | 0.020 |
Why?
|
Spleen | 1 | 2012 | 2359 | 0.020 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2007 | 264 | 0.020 |
Why?
|
Risk Management | 1 | 2009 | 571 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2011 | 2030 | 0.020 |
Why?
|
Biopsy | 1 | 1997 | 6722 | 0.020 |
Why?
|
Massachusetts | 2 | 2014 | 8669 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2010 | 1339 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5652 | 0.020 |
Why?
|
Systole | 1 | 2008 | 956 | 0.020 |
Why?
|
Periodicals as Topic | 1 | 2016 | 1428 | 0.020 |
Why?
|
Fluoroquinolones | 1 | 2007 | 306 | 0.020 |
Why?
|
Drug Resistance | 1 | 2010 | 1610 | 0.020 |
Why?
|
Enzymes | 1 | 2006 | 267 | 0.020 |
Why?
|
Regional Blood Flow | 1 | 2008 | 1528 | 0.020 |
Why?
|
Mutation | 1 | 2008 | 29658 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 1995 | 5522 | 0.010 |
Why?
|
Hospital Costs | 1 | 2010 | 982 | 0.010 |
Why?
|
Ventricular Function, Right | 1 | 2007 | 591 | 0.010 |
Why?
|
Cross-Sectional Studies | 2 | 2020 | 24714 | 0.010 |
Why?
|
Cobalt | 1 | 2003 | 159 | 0.010 |
Why?
|
Transcription Factors | 1 | 2022 | 12120 | 0.010 |
Why?
|
Glutamine | 1 | 2005 | 574 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5272 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2010 | 4743 | 0.010 |
Why?
|
Creatine Kinase | 1 | 2004 | 694 | 0.010 |
Why?
|
Psychomotor Performance | 1 | 2010 | 1899 | 0.010 |
Why?
|
Microcirculation | 1 | 2006 | 1285 | 0.010 |
Why?
|
Metabolomics | 1 | 2010 | 1460 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 1995 | 4424 | 0.010 |
Why?
|
Postoperative Care | 1 | 2008 | 1477 | 0.010 |
Why?
|
Hemodynamics | 1 | 2011 | 4197 | 0.010 |
Why?
|
Time | 1 | 2003 | 528 | 0.010 |
Why?
|
Plaque, Atherosclerotic | 1 | 2012 | 1483 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4522 | 0.010 |
Why?
|
Kinetics | 1 | 2008 | 6475 | 0.010 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2006 | 851 | 0.010 |
Why?
|
Bayes Theorem | 1 | 2008 | 2303 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6174 | 0.010 |
Why?
|
Signal Transduction | 1 | 2023 | 23355 | 0.010 |
Why?
|
Quality Improvement | 1 | 2015 | 3730 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 2012 | 3364 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 2002 | 1676 | 0.010 |
Why?
|
Canada | 1 | 2005 | 2021 | 0.010 |
Why?
|
Isoenzymes | 1 | 2004 | 1720 | 0.010 |
Why?
|
Stem Cells | 1 | 2012 | 3566 | 0.010 |
Why?
|
Lung | 1 | 1997 | 9782 | 0.010 |
Why?
|
Hyperglycemia | 1 | 2007 | 1357 | 0.010 |
Why?
|
Iatrogenic Disease | 1 | 2002 | 544 | 0.010 |
Why?
|
Nanoparticles | 1 | 2009 | 1906 | 0.010 |
Why?
|
Apoptosis | 1 | 2014 | 9714 | 0.010 |
Why?
|
Pilot Projects | 1 | 2009 | 8275 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 18125 | 0.010 |
Why?
|
Medical Records | 1 | 2001 | 1413 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6361 | 0.010 |
Why?
|
Cell Line | 1 | 2010 | 15987 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2001 | 2881 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2010 | 9387 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2014 | 7626 | 0.010 |
Why?
|
Child | 1 | 2022 | 77033 | 0.010 |
Why?
|
Crosses, Genetic | 1 | 1995 | 799 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2012 | 7136 | 0.010 |
Why?
|
Isoantigens | 1 | 1995 | 568 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2008 | 19220 | 0.010 |
Why?
|
Linear Models | 1 | 2003 | 5948 | 0.010 |
Why?
|
Rats | 1 | 2008 | 24270 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 1995 | 1883 | 0.010 |
Why?
|
Regression Analysis | 1 | 2001 | 6452 | 0.010 |
Why?
|
Protein Binding | 1 | 2003 | 9375 | 0.010 |
Why?
|
Skin Transplantation | 1 | 1995 | 1073 | 0.010 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2002 | 3344 | 0.010 |
Why?
|
Epitopes | 1 | 1995 | 2558 | 0.010 |
Why?
|
Boston | 1 | 2001 | 9314 | 0.010 |
Why?
|
Length of Stay | 1 | 2001 | 6295 | 0.000 |
Why?
|